Celgene’s most recent trend suggests a bullish bias. One trading opportunity on Celgene is a Bull Put Spread using a strike $90.50 short put and a strike $85.50 long put offers a potential 28.87% return on risk over the next 7 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $90.50 by expiration. The full premium credit of $1.12 would be kept by the premium seller. The risk of $3.88 would be incurred if the stock dropped below the $85.50 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Celgene is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Celgene is bullish.
The RSI indicator is at 73.05 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Celgene
Final Trade: CELG, BABA & more
Wed, 08 Aug 2018 22:10:00 +0000
The “Fast Money” traders share their final trades of the day, including Celgene, Alibaba, Foot Locker and Nordstrom.
Could Biotech Giant Celgene Join Tesla In The Private Markets?
Wed, 08 Aug 2018 20:17:51 +0000
Biotech giant Celgene could go private at 120 per share, an analyst suggested Wednesday after similarly sized electric-car maker Tesla confirmed it’s discussing the possibility.
Musk’s Ambitions Rekindle Celgene Privatization Musings at RBC
Wed, 08 Aug 2018 17:49:00 +0000
Elon Musk’s proposal to take Tesla Inc. private re-ignited one sell-side analyst’s thought that biotechnology giant Celgene Corp. may follow suit. RBC Capital Markets analyst Brian Abrahams revisited a concept he floated back in March that a leveraged buyout of the ailing drugmaker would enable it to capture value from its keystone cancer treatment, Revlimid, and take it out from under the microscope that is the public market. “It’s certainly a stretch to say the least,” said Bloomberg Intelligence analyst Asthika Goonewardene, noting he disagrees with the comparison of the two stocks.
A Look at Ionis’s Revenue Streams in the Second Quarter
Wed, 08 Aug 2018 15:45:02 +0000
As discussed earlier, Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to revenues of $112 million during the second quarter of 2017. Ionis missed Wall Street analyst estimates for revenues and EPS in Q2 2018. Ionis reported commercial revenues of $57 million during Q2 2018, over 100% growth as compared to commercial revenues of $24 million during the second quarter of 2017.
Protagonist Stock Jumps 58% After Re-Review of Test Results
Wed, 08 Aug 2018 15:21:42 +0000
The mouth-watering 58% rise in shares of Protagonist Therapeutics (NASDAQ:PTGX) on Monday should interest biotech investors. At a market cap of $236.2 million, experienced biotech investors will expect higher than normal volatility. On Monday, Protagonist announced that it secured $22 million in equity financing through the sale of 2.75 million shares.
Follow Us on Facebook